Immunology Program
The Alexander Rudensky Lab
Research
Our research is focused on understanding the molecular mechanisms governing the differentiation and function of CD4 T lymphocytes and their role in immunity and tolerance. Major areas of interest include: the molecular and cellular mechanisms governing the differentiation and function of regulatory T cells; the roles these cells play in control of autoimmunity, tumor immunity, and immunity to infections, and in the maintenance of immune homeostasis at environmental interfaces. We are particularly interested in understanding the role of the forkhead family transcription factor Foxp3 in establishing and maintaining immune homeostasis; and in the plasticity of regulatory T cell transcriptional and functional programs and the molecular mechanisms of regulatory T cell lineage stability.
Featured News
Publications
People
Alexander Rudensky, PhD
Chair, Immunology Program, SKI; Director, Ludwig Center at MSK
- Immunology Program Chair Alexander Rudensky focuses on immunological tolerance and the differentiation and function of T cells.
- PhD, Gabrichevsky Institute for Microbiology and Epidemiology
- rudenska@mskcc.org
- Email Address
- 646-888-3109
- Office Phone
Members
- BSc, The University of Hong Kong
- The University of British Columbia
Lab Alumni
Lab Affiliations
Achievements
- Investigator, Howard Hughes Medical Institute
- Vilcek Prize in Biomedical Science, New York, NY (2018)
- Crafoord Prize, the Royal Swedish Academy of Sciences, Stockholm Sweden (2017)
- Member, National Academy of Medicine (2015)
- Member, American Academy of Arts and Sciences (2015)
Read more
- Coley Award in Basic Immunology, Cancer Research Institute (2015)
- Thomson Reuters Citation Laureate (2015)
- Member, National Academy of Sciences (2012)
- Merit Award, National Institutes of Health (2009)
- Investigator Award, American Association of Immunologists/PharMingen (1999)
- Searle Scholar Award (1993)
- Investigator, Howard Hughes Medical Institute (1993)
- Elucidation of the function of transcription factor Foxp3 in regulatory T cells and their critical role in immune homeostasis (2003-2010)
- Identification of the primary structure of MHC class II bound peptides (1991)
Get in Touch
-
Lab Head Email
-
Office Phone
-
Office Fax
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Alexander Rudensky discloses the following relationships and financial interests:
-
BioInvent International AB
Provision of Services -
Omeros
Provision of Services -
RAPT Therapeutics
Ownership / Equity Interests; Provision of Services -
Sonoma Biotherapeutics, Inc.
Ownership / Equity Interests; Provision of Services
-
Surface Oncology
Ownership / Equity Interests; Provision of Services -
Takeda Pharmaceuticals
Intellectual Property Rights -
Vedanta
Ownership / Equity Interests; Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.